American Diabetes Association’s 71st Scientific Sessions
June 24–28, 2011 – San Diego Convention Center
The Immune Tolerance Network is conducting a portfolio of innovative intervention research trials in new-onset type 1 diabetes.
Join us for the following preliminary trial result presentations:
Tuesday, June 28th
AbATE Study (hOKT3γ1(Ala-Ala); teplizumab), by Kevan Herold, MD and Stephen Gitelman, MD.
Monday, June 27th
Rapamycin plus IL-2 combination therapy in subjects with T1D results in a sustained increase in IL-2 responsiveness and a transient decrease in C-peptide levels, by Carla Greenbaum, MD